News
2019.11.15
The President of COREE Group, Chongyoon-Lim, signed a "Special Fund for the Prevention and Treatment of Metabolic Diseases" with Peking Union Medical Foundation.
It covers GDM and more specific, broader research protocols.
Figure: President Chongyoon-Lim (6th from the left) and Chairman Jiang Yu-xin (7th from the left) took a photo with the Head of COREE Group and the project participating team of Peking Union Medical Foundation
On November 15, 2019, Peking Union Medical Foundation-COREE Group (an affiliate of Hanmi Pharmaceutical Group) Metabolic Diseases Prevention and Treatment Research Special Fund was officially announced.
The Special Fund aims to further improve the prevention and treatment of maternal and infant metabolic diseases, reduce birth defects and protect maternal and infant health. The signing ceremony was held at the Telemedicine Center of Peking Union Medical College Hospital, Chairman of Peking Union Medical Foundation Jiang Yu-xin, Professor of Obstetrics and Gynecology in Peking Union Medical College Hospital Xu Ling, the Head of the Special Fund Ma Liangkun, Founder of COREE Group Chongyoon-Lim (President of Korean Biological Association and Representative Director of Hanmi Group), the Head of COREE Group, and other relevant representatives attended the signing ceremony.
Figure: Jiang Yu-xin (right), Chairman of Peking Union Medical Foundation, presented certificate of appreciation to Chongyoon-Lim (left), who is the President of Korean Biological Association, the founder of COREE Group and the representative director of Hanmi Group
The COREE Group, founded by Representative Chongyoon-Lim of Hanmi Science, is a global company with subsidiaries in Asia, Europe and the Americas that conducts research, investment and expands new business orientations. COREE Group owns the Bio-Health Consulting Systems "COREE Therapeutics" and "Therapy R&D Center" developed in cooperation with world-class hospitals and global medical experts. The world's first Biobank "MOTHER AND CHILD AND BEYOND BIO BANK" for puerpera and children was established in China and Italy in 2017.
Peking Union Medical Foundation-COREE Group Metabolic Disease Prevention and Treatment and Research Special Fund mainly studies on maternal and infant metabolic diseases pathogenesis, maternal and infant metabolic diseases genetic correlation and maternal and infant metabolic diseases prevention and treatment programs.
Especially for Gestational Diabetes Mellitus (GDM), which has not been identified as the reason why drug treatment cannot be carried out during pregnancy, the fundamental treatment and research should be carried out.
Pregnant women with GDM account for about 10% of pregnant women. So the research and treatment of it need to be paid attention at the early diagnosis of disease. The report indicates that if GDM is not treated, children are more likely to develop metabolic diseases in the future. The aim of the joint study is to renovate technologies that could be used to treat GDM without drug treatment for maternal and infant.
COREE Group and Peking Union Medical Foundation will promote the innovation model of mobile medical service in maternal and infant field and construct the maternal and infant health database at the same time.
Beijing Hanmi Pharmaceuticals represented by Ofmom, the core brand of "BIO South Korean Trend", led by Representative Chongyoon-Lim, has joined hands with COREE Group to make the prospect of this cooperation even more worthy of expectation. The industry forecasts that COREE Group, Hanmi Science and Beijing Hanmi pharmaceutical-related pharmaceutical production and "Personalized Therapy" proposed by Representative Chongyoon-Lim will become a new medical innovation model in the future.
The Head of the COREE Group stated: The collaborative study is a program for the prevention and treatment of metabolic diseases focusing on maternal and child.
The establishment of the Special Fund will introduce specific mass medical services and prevention and treatment interventions, for which purpose information is being obtained on the application of medical insurance. If health management during pregnancy and childbirth, growth (including the prevention and treatment of metabolic diseases such as GDM etc.) can be covered by health insurance, which will have a positive impact research on low fertility, diabetes and obesity, and metabolic diseases. Therefore, communication and applications are being planned with the relevant authorities.